ET
CRSP icon

Entropy Technologies’s CRISPR Therapeutics CRSP Stock Holding History

Entropy Technologies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$669K Buy
+14,067
New +$742K 0.03% 527
2025
Q3 		– Sell
-21,696
Closed -$1.06M – 868
2025
Q2 		$1.06M Buy
+21,696
New +$840K 0.08% 295
2024
Q4 		– Sell
-7,905
Closed -$371K – 780
2024
Q3 		$371K Sell
7,905
-7,497
-49% -$380K 0.04% 512
2024
Q2 		$832K Sell
15,402
-9,878
-39% -$571K 0.09% 275
2024
Q1 		$1.72M Buy
+25,280
New +$1.81M 0.18% 162

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Entropy Technologies's CRSP Position: Q1 2026 in Review

Entropy Technologies opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 14,067 shares worth $669K. The stake represents 0.03% of the portfolio and ranks #527 among its holdings. This is a return to the name: Entropy Technologies previously reported a position in CRSP as recently as Q2 2025.

Entropy Technologies first reported a position in CRSP in Q1 2024 and has held it in 5 quarters since. The position peaked at $1.72M in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Entropy Technologies held 14,067 shares of CRISPR Therapeutics worth $669K as of Q1 2026.
  • CRISPR Therapeutics was a new Entropy Technologies position in Q1 2026.
  • CRISPR Therapeutics made up 0.03% of Entropy Technologies's portfolio in Q1 2026, its #527 holding.
  • Entropy Technologies first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Entropy Technologies's CRISPR Therapeutics position peaked at $1.72M in Q1 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.